PubRank

Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Clinical Trial ID NCT00110214

PubWeight™ 22.55‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00110214

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012 3.73
2 Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 2011 1.98
3 Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2010 1.86
4 New developments in the medical management of prostate cancer. Mayo Clin Proc 2010 1.41
5 Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med 2012 1.20
6 Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer. Cancer J 2013 1.09
7 Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett 2009 1.04
8 The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer. BJU Int 2012 1.00
9 Update on options for treatment of metastatic castration-resistant prostate cancer. Onco Targets Ther 2010 1.00
10 Overcoming drug resistance and treating advanced prostate cancer. Curr Drug Targets 2012 0.95
11 Anti-angiogenesis approach to genitourinary cancer treatment. Update Cancer Ther 2009 0.92
12 Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci 2013 0.88
13 Angiogenesis inhibition in prostate cancer: current uses and future promises. J Oncol 2010 0.87
14 Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences. J Clin Oncol 2013 0.87
15 Angiogenesis inhibitors in the treatment of prostate cancer. Expert Opin Pharmacother 2010 0.86
16 Recent developments in prostate cancer biomarker research: therapeutic implications. Br J Clin Pharmacol 2011 0.86
17 Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer 2013 0.83
18 Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol (Lausanne) 2012 0.81
19 Research in castration-resistant prostate cancer: what does the future hold? Curr Oncol 2010 0.79
Next 100